Compare Ares Capital Corporation (ARCC) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Intuitive Surgical, Inc. — how do they compare? Ares Capital Corporation trades at $18.75 (market cap $13.48B), while Intuitive Surgical, Inc. trades at $408.5 (market cap $144.07B). The key difference: Intuitive Surgical, Inc. is far larger — about 10.7× Ares Capital Corporation's market cap, and Ares Capital Corporation pays a 10.22% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| ARCC | ISRG | |
|---|---|---|
Market Cap | $13.48B | $144.07B |
Sector | Financials | Health |
52-Week High | $23.25 | $592.85 |
52-Week Low | $17.45 | $397.68 |
Dividend Yield | 10.22% | — |
Enterprise Value | — | $139.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ares Capital (ARCC) trades at $18.78, up 2.01% on the day, with a bearish technical signal but strong analyst support. The stock shows a P/E of 11.52 and P/B of 0.96, trading below the consensus price target of $20.58. Recent earnings have missed expectations, with Q2 2026 results pending, while revenue declined to $1.51B in 2025 from $1.7B in 2024. A dividend of $0.48 is scheduled for payment on June 30, 2026, supporting income appeal amid mixed sentiment.
ARCC presents a value opportunity with a high dividend yield and undervaluation relative to analyst targets, but faces headwinds from earnings misses and a bearish technical outlook. Risks include revenue volatility and competitive pressures in the BDC space, though institutional buy ratings suggest confidence in recovery potential. Investors should weigh income stability against growth challenges.
Intuitive Surgical (ISRG) trades at $406.78, down 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings of $2.50 EPS, beating estimates, with revenue reaching $10.06 billion in 2025 and net income margin at 28.15%. Analyst consensus is bullish with a $556.10 price target, though valuation ratios like P/E of 49.43 remain elevated. Recent news highlights Q2 2026 earnings anticipation on July 16 and ongoing adoption of da Vinci 5 systems.
Outlook is positive due to consistent earnings beats and robust revenue growth, but risks include high valuation sensitivity and competitive pressures. The stock offers long-term growth potential in robotic surgery, yet investors should monitor margin trends and quarterly results for sustained momentum amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
